Karin Thevissen

15PUBLICATIONS
132CO-AUTHORS
Molecular targetsGlycoconjugatesMedical infection agents (incl. prions)Infectious agentsMicrofluidics and nanofluidics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 05, 2025
Clioquinol as a new therapy in epilepsy: From preclinical evidence to a proof-of-concept clinical study.

Karin Thevissen, Annelii Ny, Daniëlle Copmans

|Feb 12, 2025
The antimicrobial activity of ETD151 defensin is dictated by the presence of glycosphingolipids in the targeted organisms.

Ons Kharrat, Yoshiki Yamaryo-Botté, Rouba Nasreddine

|Oct 25, 2024
Imidazoles and Quaternary Ammonium Compounds as Effective Therapies against (Multidrug-Resistant) Bacterial Wound Infections.

Lauren Van de Vliet, Thijs Vackier, Karin Thevissen

|Jun 12, 2024
Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis.

Simon Feys, Martina Cardinali-Benigni, Hanne Moon Lauwers

|Feb 15, 2022
Multiplex Analysis to Unravel the Mode of Antifungal Activity of the Plant Defensin HsAFP1 in Single Yeast Cells.

Caroline Struyfs, Jolien Breukers, Dragana Spasic

Pageof 3